Novel injectable sodium alginate hydrogel developed for improved endometrial repair with human umbilical cord mesenchymal stem cells.

IF 5.7 3区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Drug Delivery and Translational Research Pub Date : 2025-04-07 DOI:10.1007/s13346-025-01846-4

Yifan Li, Weimin Yin, Haiqing Dong, Rongxiang Wang, Lihua Sun, Yongyong Li, Jing Xie

引用次数: 0

Abstract

This study presents a novel injectable sodium alginate hydrogel designed to enhanc stem cell therapy for endometrial regeneration. Using calcium gluconate as a crosslinking agent, we achieved improved homogeneity and injectability compared to traditional calcium chloride crosslinking. RGD modification further enhanced cell adhesion, proliferation, and differentiation in vitro, creating a bioactive scaffold for umbilical cord mesenchymal stem cells (UCMSCs) delivery. In a mouse model of endometrial injury, intrauterine transplantation of RGD-modified hydrogel encapsulating UCMSCs significantly improved endometrial thickness, reduced fibrosis, enhanced angiogenesis, and increased pregnancy rates compared to both untreated controls and UCMSCs alone. These results suggest that this injectable hydrogel system combined with stem cells holds significant promise for future applications in treating endometrial damage and improving reproductive outcomes in women.

查看原文本刊更多论文

本研究介绍了一种新型可注射海藻酸钠水凝胶，旨在增强干细胞治疗子宫内膜再生的效果。与传统的氯化钙交联相比，我们使用葡萄糖酸钙作为交联剂，提高了水凝胶的均匀性和可注射性。RGD 修饰进一步增强了细胞在体外的粘附、增殖和分化，为脐带间充质干细胞（UCMSCs）的输送创造了一种生物活性支架。在小鼠子宫内膜损伤模型中，与未经处理的对照组和单独的脐带间充质干细胞相比，宫腔内移植包裹脐带间充质干细胞的RGD修饰水凝胶可显著改善子宫内膜厚度、减少纤维化、增强血管生成并提高妊娠率。这些结果表明，这种与干细胞相结合的可注射水凝胶系统在未来治疗子宫内膜损伤和改善妇女生殖结果方面的应用前景广阔。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Delivery and Translational Research MEDICINE, RESEARCH & EXPERIMENTALPHARMACOL-PHARMACOLOGY & PHARMACY

CiteScore

11.70

自引率

1.90%

发文量

160

期刊介绍： The journal provides a unique forum for scientific publication of high-quality research that is exclusively focused on translational aspects of drug delivery. Rationally developed, effective delivery systems can potentially affect clinical outcome in different disease conditions. Research focused on the following areas of translational drug delivery research will be considered for publication in the journal. Designing and developing novel drug delivery systems, with a focus on their application to disease conditions; Preclinical and clinical data related to drug delivery systems; Drug distribution, pharmacokinetics, clearance, with drug delivery systems as compared to traditional dosing to demonstrate beneficial outcomes Short-term and long-term biocompatibility of drug delivery systems, host response; Biomaterials with growth factors for stem-cell differentiation in regenerative medicine and tissue engineering; Image-guided drug therapy, Nanomedicine; Devices for drug delivery and drug/device combination products. In addition to original full-length papers, communications, and reviews, the journal includes editorials, reports of future meetings, research highlights, and announcements pertaining to the activities of the Controlled Release Society.